Published in Inflamm Bowel Dis on August 01, 2006
Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol (2014) 1.19
Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol (2007) 1.12
Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol (2010) 1.02
Old-age inflammatory bowel disease onset: a different problem? World J Gastroenterol (2011) 1.00
Low body mass index can identify majority of osteoporotic inflammatory bowel disease patients missed by current guidelines. ScientificWorldJournal (2012) 0.95
Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations. MedGenMed (2007) 0.94
Lower gastrointestinal bleeding in the elderly. World J Gastrointest Endosc (2010) 0.93
Osteoporosis in adult Sri Lankan inflammatory bowel disease patients. World J Gastroenterol (2009) 0.85
Low bone mineral density in Greek patients with inflammatory bowel disease: prevalence and risk factors. Ann Gastroenterol (2011) 0.80
What is the impact of age on adult patients with inflammatory bowel disease? Clujul Med (2013) 0.77
Increased fracture risk assessed by fracture risk assessment tool in Greek patients with Crohn's disease. Dig Dis Sci (2012) 0.77
Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther (2016) 0.76
Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study. Medicine (Baltimore) (2017) 0.75
Importance of negative trials. Inflamm Bowel Dis (2007) 0.75
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 5.66
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Possible association between isotretinoin and inflammatory bowel disease. Am J Gastroenterol (2006) 2.97
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol (2009) 2.72
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology (2005) 2.05
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
The risk of developing Crohn's disease after an appendectomy: a meta-analysis. Am J Gastroenterol (2008) 1.74
Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology (2007) 1.71
Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res (2012) 1.70
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology (2007) 1.60
Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology (2008) 1.56
Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis (2010) 1.42
Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class? JAMA Intern Med (2013) 1.40
Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol (2004) 1.25
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis (2011) 1.22
Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists. J Pediatr Gastroenterol Nutr (2009) 1.22
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol (2012) 1.22
Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease. Am J Gastroenterol (2006) 1.21
The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol (2010) 1.19
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15
Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology (2012) 1.15
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis (2011) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.13
Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal (2008) 1.13
Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm (2010) 1.11
Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg (2008) 1.09
Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted. BMJ (2013) 1.06
Risk factors for colorectal cancer in Crohn's colitis: a case-control study. Inflamm Bowel Dis (2006) 1.05
Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford) (2013) 1.00
Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials? Inflamm Bowel Dis (2012) 1.00
Acute appendicitis following colonoscopy. J Clin Gastroenterol (2005) 1.00
Risk factors for colon ischemia. Am J Gastroenterol (2004) 1.00
A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2006) 0.99
State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis (2005) 0.98
Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut (2011) 0.97
A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol (2013) 0.96
The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and Denmark. Gut (2007) 0.96
When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis (2010) 0.93
Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Am J Gastroenterol (2003) 0.92
Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol (2007) 0.92
Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrob Agents Chemother (2003) 0.92
Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis (2011) 0.89
Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. J Crohns Colitis (2013) 0.86
Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol (2011) 0.85
Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol (2008) 0.85
Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire. Inflamm Bowel Dis (2009) 0.85
Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factors. Scand J Gastroenterol (2015) 0.84
Efficacy of methotrexate in ulcerative colitis: failure or promise. Inflamm Bowel Dis (2010) 0.83
Challenges in designing a national surveillance program for inflammatory bowel disease in the United States. Inflamm Bowel Dis (2014) 0.83
Calcium supplements controversy in osteoporosis: a physiological mechanism supporting cardiovascular adverse effects. Endocrine (2015) 0.83
Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis. Liver Int (2005) 0.82
Effects of growth hormone secretion on body composition in patients with Crohn's disease. J Clin Endocrinol Metab (2003) 0.82
Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease? Surgery (2011) 0.81
Menstrual cycle changes in women with inflammatory bowel disease: a study from the ocean state Crohn's and colitis area registry. Inflamm Bowel Dis (2014) 0.80
Genetics, Genetic Testing, and Biomarkers of Digestive Diseases. Gastroenterology (2015) 0.80
Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2013) 0.80
Serum Proteome Profiles in Stricturing Crohn's Disease: A Pilot Study. Inflamm Bowel Dis (2015) 0.80
Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis (2010) 0.78
Testing for Clostridium difficile in patients newly diagnosed with inflammatory bowel disease in a community setting. Inflamm Bowel Dis (2015) 0.78
Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial. JMIR Res Protoc (2015) 0.78
Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study. Inflamm Bowel Dis (2017) 0.78
Body image dissatisfaction in patients with inflammatory bowel disease. Inflamm Bowel Dis (2015) 0.77
Babesiosis in a patient on infliximab for Crohn's disease. Inflamm Bowel Dis (2010) 0.77
Anti-TNFα therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis (2014) 0.77
Systemic inflammatory mediators and bone homeostasis in intestinal failure. JPEN J Parenter Enteral Nutr (2007) 0.77
Evaluation of possible inflammatory bowel disease: a survey of Rhode Island physicians. Med Health R I (2012) 0.77
Within you, without you: is gastroenterology ready to embrace the "exposome"? Gastroenterology (2012) 0.76
High-dose oral vitamin D supplementation and risk of falls in older women. JAMA (2010) 0.75
Macrophages in Hodgkin's lymphoma. N Engl J Med (2010) 0.75
Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and Answers. Inflamm Bowel Dis (2016) 0.75
Achieving Synergy: Linking an Internet-Based Inflammatory Bowel Disease Cohort to a Community-Based Inception Cohort and Multicentered Cohort in Inflammatory Bowel Disease. J Med Internet Res (2016) 0.75
Incidence of Crohn's Disease and Ulcerative Colitis in Rhode Island: Report from the Ocean State Crohn's and Colitis Area Registry. Inflamm Bowel Dis (2016) 0.75
Two underlying diseases causing hypercalcaemia? Nephrol Dial Transplant (2002) 0.75
Calcific aortic stenosis. N Engl J Med (2009) 0.75
Periodontal Disease, Dental Implants, Extractions and Medications Related to Osteonecrosis of the Jaws. Dent Update (2015) 0.75
Acute renal failure and hypercalcaemia in a man from Guyana: what is the link? Nephrol Dial Transplant (2005) 0.75
Predictors of Hospital Readmissions for Ulcerative Colitis in the United States: A National Database Study. Inflamm Bowel Dis (2017) 0.75
Oestrogens and ageing from the skeletal prospective. Postgrad Med J (2017) 0.75
Association between the use of serotonin receptor 2A-blocking antidepressants and joint disorders: comment on the article by Kling et al. Arthritis Care Res (Hoboken) (2010) 0.75